07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Necuparanib: Development discontinued

Momenta discontinued its necuparanib program after confirming the results of an independent DSMB’s interim futility analysis and reviewing the unblinded safety and efficacy data from a double-blind, placebo-controlled, North American Phase I/II trial evaluating once-daily...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

Necuparanib: Phase I/II discontinued

Momenta discontinued enrollment in the Phase II portion of a double-blind, placebo-controlled, North American Phase I/II trial of necuparanib after an independent DSMB’s planned futility analysis showed that a combination including necuparanib “did not show...
07:00 , Aug 4, 2016 |  BC Extra  |  Clinical News

Momenta's necuparanib fails pancreatic cancer trial

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) fell $0.63 to $11.11 on Thursday after it said it will discontinue enrollment in the Phase II portion of a Phase I/II study of necuparanib ( M402 ) to treat metastatic...
07:00 , May 26, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Plasma and urine levels of heparan sulfate 6-O-sulfotransferase 2 (HS6ST2), chondroitin polymerizing factor 2 (CHPF2) and exostosin-like glycosyltra

Biomarkers TECHNOLOGY: Diagnostic assays A method of scoring plasma and urine levels of HS6ST2 , CHPF2 and EXTL1 could help diagnose metastatic ccRCC. Genome-wide analysis of tissue samples from 481 ccRCC patients identified multiple genes...
07:00 , Apr 7, 2016 |  BC Innovations  |  Product R&D

Branching out

With its second compound about to hit the clinic and a fresh influx of money, Symic Biomedical Inc. is lining up the next three preclinical programs for its extracellular matrix (ECM)-targeting technology. By applying each...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Necuparanib: Phase I/II delayed

Momenta temporarily paused enrollment in the Phase II portion of a double-blind, placebo-controlled, North American Phase I/II trial of oral necuparanib following an independent DSMB recommendation. The company expects to resume enrollment after instituting a...
01:56 , Nov 14, 2015 |  BC Extra  |  Clinical News

Momenta pauses enrollment in necuparanib trial

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it temporarily paused enrollment in the Phase II portion of a Phase I/II trial of necuparanib ( M402 ) to treat metastatic pancreatic cancer. The company expects to resume enrollment...
07:00 , Sep 28, 2015 |  BioCentury  |  Product Development

Sailing on in Sanfilippo

uniQure N.V. says Phase I/II data on AMT-110 support both the start of a pivotal trial for Sanfilippo type B syndrome, and the company's plans to use its AAV5 vector in other rare lysosomal storage...
07:00 , Mar 23, 2015 |  BioCentury  |  Emerging Company Profile

Complementary edge

The neurological manifestations of many lysosomal storage disorders are poorly treated because it hasn't been possible to get enough of an enzyme or gene therapy vector across the blood-brain barrier to replace dysfunctional proteins. Abeona...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

Necuparanib regulatory update

FDA granted Fast Track designation to necuparanib from Momenta for first-line treatment of metastatic pancreatic cancer in combination with Abraxane nab-paclitaxel and gemcitabine. The heparin sulfate glycosaminoglycan ( HSGAG ) mimetic engineered from low molecular...